Osimertinib Therapy After Resection in High-risk Stage I EGFRm NSCLC (OSTAR)

NCT05686434 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

65

Enrollment

OTHER

Sponsor class

Conditions

NSCLC, Stage I

Interventions

DRUG: Osimertinib

Sponsor

Tianjin Medical University Cancer Institute and Hospital